Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Annals of Hematology|January 13, 2025
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia veraAbdulraheem Yacoub, Ghaith Abu-Zeinah, Albert Qin, et al.
Pharmaceutics|October 27, 2022
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I ResultsJin-Bon Hong, Po-Yuan Wu, Albert Qin, et al.
International Journal of Hematology|October 3, 2024
Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia veraKeita Kirito, Yuka Sugimoto, Akihiko Gotoh, et al.
Frontiers in Pharmacology|October 10, 2024
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2bAlbert Qin, Daoxiang Wu, Jason Liao, et al.
Future Oncology (London, England)|August 4, 2022
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemiaSrdan Verstovsek, Norio Komatsu, Harinder Gill, et al.
International Journal of Hematology|March 9, 2026
Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter studyTadaaki Inano, Yuka Sugimoto, Kohshi Ohishi, et al.
Advances in Therapy|December 15, 2021
Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in TaiwanKuan-Yuan Chen, Kang-Yun Lee, Albert Qin, et al.
International Journal of Hematology|April 17, 2022
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 studyYoko Edahiro, Kohshi Ohishi, Akihiko Gotoh, et al.
Pharmacology Research & Perspectives|May 2, 2025
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia VeraAlbert Qin, Kazuya Shimoda, Shanshan Suo, et al.
Hepatology International|October 25, 2020
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis BYi-Wen Huang, Chao-Wei Hsu, Sheng-Nan Lu, et al.
Pageof 5